Cara Therapeutics price target raised to $29 from $25 at Canaccord Canaccord raised its price target on Cara Therapeutics to $29 from $25 on the CRS-45's potential in adjunct post-operative pain relief. The firm expects positive Phase 3 data in the second half of 2015 and could have potential US sales of $750M. Shares are Buy rated.
Cara Therapeutics files to sell $65M in common stock Stifel and Piper Jaffray & Co. are acting as joint book-running managers for the proposed offering. Canaccord Genuity Inc., Needham & Company, LLC and Janney Montgomery Scott LLC are acting as co-managers.